What Black Myeloma Patients Should Know About Antibody Drug Conjugates

New myeloma treatments are advancing quickly, but many Black patients are still left trying to piece together information on their own while navigating questions about access, trust, side effects, cost, and whether these treatments are even realistic options for them.

Antibody drug conjugates (ADCs) are an emerging therapy in multiple myeloma, yet many patients have never had these treatments clearly explained in a way that feels practical, relatable, and centered on real patient concerns.

Join Dr. Sakander Ailawadhi from Mao Clinic Jacksonville for an open, patient-centered conversation created specifically for Black myeloma patients and caregivers. This session will break down what antibody drug conjugates are, how they work, who may be eligible, possible side effects, and important questions patients should consider when discussing treatment options with their healthcare team.

This discussion is part of HealthTree’s ongoing commitment to improving education, awareness, and informed decision-making within the Black myeloma community. Our goal is not only to share information, but to help patients feel more confident asking questions, understanding their options, and navigating care.

Participants will be asked to complete a brief survey before and after the session to help us better understand how education can support Black patients in making informed treatment decisions.

Register, complete the survey, and come ready with your questions.

If your HealthTree profile is not fully completed beyond registration, you may be asked to provide a few additional details before accessing the survey. This may include basic demographic information and information about your care, such as where you are being treated.